Sana Biotechnology Competitors

AbCellera Biologics (NASDAQ:ABCL) and Sana Biotechnology (NASDAQ:SANA) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Valuation and Earnings

This table compares AbCellera Biologics and Sana Biotechnology's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings for AbCellera Biologics and Sana Biotechnology, as provided by MarketBeat.

AbCellera Biologics presently has a consensus price target of $52.80, suggesting a potential upside of 90.41%. Sana Biotechnology has a consensus price target of $40.00, suggesting a potential upside of 72.19%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Sana Biotechnology.

Profitability

This table compares AbCellera Biologics and Sana Biotechnology's net margins, return on equity and return on assets.

Summary

AbCellera Biologics beats Sana Biotechnology on 3 of the 3 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sana Biotechnology and Abcam, as provided by MarketBeat.

Sana Biotechnology presently has a consensus price target of $40.00, indicating a potential upside of 72.19%. Abcam has a consensus price target of $22.00, indicating a potential upside of 9.29%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Abcam.

Valuation & Earnings

This table compares Sana Biotechnology and Abcam's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Sana Biotechnology and Abcam's net margins, return on equity and return on assets.

Summary

Sana Biotechnology beats Abcam on 2 of the 3 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Seer (NASDAQ:SEER) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Sana Biotechnology and Seer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Sana Biotechnology and Seer's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sana Biotechnology and Seer, as provided by MarketBeat.com.

Sana Biotechnology presently has a consensus price target of $40.00, suggesting a potential upside of 72.19%. Seer has a consensus price target of $68.00, suggesting a potential upside of 40.76%. Given Sana Biotechnology's higher probable upside, equities research analysts plainly believe Sana Biotechnology is more favorable than Seer.

Summary

Sana Biotechnology beats Seer on 1 of the 1 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Sana Biotechnology (NASDAQ:SANA) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Nuvation Bio and Sana Biotechnology's top-line revenue, earnings per share and valuation.

Profitability

This table compares Nuvation Bio and Sana Biotechnology's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nuvation Bio and Sana Biotechnology, as provided by MarketBeat.com.

Nuvation Bio presently has a consensus target price of $17.40, suggesting a potential upside of 69.92%. Sana Biotechnology has a consensus target price of $40.00, suggesting a potential upside of 72.19%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Nuvation Bio.

Summary

Nuvation Bio beats Sana Biotechnology on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Profitability

This table compares ImmunityBio and Sana Biotechnology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ImmunityBio and Sana Biotechnology, as provided by MarketBeat.com.

ImmunityBio presently has a consensus price target of $25.00, indicating a potential upside of 50.15%. Sana Biotechnology has a consensus price target of $40.00, indicating a potential upside of 72.19%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than ImmunityBio.

Earnings & Valuation

This table compares ImmunityBio and Sana Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Summary

Sana Biotechnology beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and Sana Biotechnology, as reported by MarketBeat.

Immunocore currently has a consensus target price of $54.3333, indicating a potential upside of 45.67%. Sana Biotechnology has a consensus target price of $40.00, indicating a potential upside of 72.19%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Immunocore.

Earnings & Valuation

This table compares Immunocore and Sana Biotechnology's top-line revenue, earnings per share and valuation.

Profitability

This table compares Immunocore and Sana Biotechnology's net margins, return on equity and return on assets.